These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

965 related articles for article (PubMed ID: 27189798)

  • 21. Genetics of Cystic Fibrosis: Clinical Implications.
    Egan ME
    Clin Chest Med; 2016 Mar; 37(1):9-16. PubMed ID: 26857764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis.
    Bishop MD; Freedman SD; Zielenski J; Ahmed N; Dupuis A; Martin S; Ellis L; Shea J; Hopper I; Corey M; Kortan P; Haber G; Ross C; Tzountzouris J; Steele L; Ray PN; Tsui LC; Durie PR
    Hum Genet; 2005 Dec; 118(3-4):372-81. PubMed ID: 16193325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Functional characterization of naturally occurring CFTR mutants: interest for cystic fibrosis].
    Romey MC
    Ann Biol Clin (Paris); 2006; 64(5):429-37. PubMed ID: 17040873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repairing the basic defect in cystic fibrosis - one approach is not enough.
    Farinha CM; Matos P
    FEBS J; 2016 Jan; 283(2):246-64. PubMed ID: 26416076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cystic fibrosis.
    Elborn JS
    Lancet; 2016 Nov; 388(10059):2519-2531. PubMed ID: 27140670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cystic fibrosis modifying genes].
    Knauer N; Ratjen F; Grasemann H
    Pneumologie; 2005 Jun; 59(6):395-404. PubMed ID: 15991075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis.
    Ooi CY; Durie PR
    J Cyst Fibros; 2012 Sep; 11(5):355-62. PubMed ID: 22658665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The impact of hypoxia on the ion channels in cystic fibrosis bronchial epithelial cells].
    Pascarel K; Colas J; Mirval S; Becq F; Vandebrouck C
    Rev Mal Respir; 2023 Mar; 40(3):230-233. PubMed ID: 36775781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding how cystic fibrosis mutations disrupt CFTR function: from single molecules to animal models.
    Wang Y; Wrennall JA; Cai Z; Li H; Sheppard DN
    Int J Biochem Cell Biol; 2014 Jul; 52():47-57. PubMed ID: 24727426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel CFTR Mutations in Two Iranian Families with Severe Cystic Fibrosis.
    Mohseni M; Razzaghmanesh M; Parsi Mehr E; Zare H; Beheshtian M; Najmabadi H
    Iran Biomed J; 2016 Sep; 20(4):201-6. PubMed ID: 27017198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type I, II, III, IV, and V cystic fibrosis transmembrane conductance regulator defects and opportunities for therapy.
    Choo-Kang LR; Zeitlin PL
    Curr Opin Pulm Med; 2000 Nov; 6(6):521-9. PubMed ID: 11100963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the Root Cause of Cystic Fibrosis.
    Trescott L; Holcomb J; Spellmon N; Mcleod C; Aljehane L; Sun F; Li C; Yang Z
    Curr Drug Targets; 2015; 16(9):933-44. PubMed ID: 25316272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators.
    Fajac I; Sermet I
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New horizons for cystic fibrosis treatment.
    Fajac I; De Boeck K
    Pharmacol Ther; 2017 Feb; 170():205-211. PubMed ID: 27916649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene therapy in cystic fibrosis.
    Prickett M; Jain M
    Transl Res; 2013 Apr; 161(4):255-64. PubMed ID: 23273902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular complications in cystic fibrosis: A review of the literature.
    Poore TS; Taylor-Cousar JL; Zemanick ET
    J Cyst Fibros; 2022 Jan; 21(1):18-25. PubMed ID: 34140249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.